



DEPARTMENT OF HEALTH & HUMAN SERVICES

Patent Term
Public Health Service



NOV - 4 1998

Food and Drug Administration
Rockville MD 20857

#25

Re: Avapro®
Docket No.: 98E-0781

The Honorable Bruce Lehman
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED
NOV 20 1998
OFFICE OF PETITIONS
DEPUTY A/C PATENTS

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 5,270,317, filed by Sanofi, under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Avapro®, the human drug product claimed by the patent.

The total length of the regulatory review period for Avapro® is 1,616 days. Of this time, 1,246 days occurred during the testing phase and 370 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: April 30, 1993.

FDA has verified the applicant's claim that the date the Investigational New Drug application became effective was on April 30, 1993.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: September 26, 1996.

FDA has verified the applicant's claim that the New Drug Application (NDA) for Avapro® (NDA 20-757) was initially submitted on September 26, 1996.


3. The date the application was approved: September 30, 1997.

FDA has verified the applicant's claim that NDA 20-757 was approved on September 30, 1997.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, reading "Thomas J. McGinnis". The signature is written in a cursive style with a large, stylized "T" and "M".

Thomas J. McGinnis, R.Ph.
Deputy Associate Commissioner
for Health Affairs

cc: Michael D. Alexander
Sanofi Pharmaceuticals, Inc.
9 Great Valley Parkway
Malvern, PA 19355